Reprocell USA to support Lantern Pharma’s Phase 2 clinical trial
Reprocell USA, a contract research organisation (CRO), has been awarded a contract to support Lantern Pharma’s Phase 2 clinical trial for its investigational new drug LP-300 in combination with carboplatin and pemetrexed.